Joseph Cursons
8 Papers
5 Citations
Joseph Cursons is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Shikhar Sharma,Chi-Yeh Chung,S. Uryu,Jelena D. Petrović,Joan Q. Cao,Amanda Rickard,N. Nady,S.E. Greasley,Eric D. Johnson,O. Brodsky,Showkhin Khan,Hui Wang,Zhenxiong Wang,Yong Zhang,Konstantinos E. Tsaparikos,Lei Chen,Anthony Mazurek,John D. Lapek,Pei-Pei Kung,S. Sutton,Paul F. Richardson,Eric Greenwald,Shin Yamazaki,Rhys Jones,K. Maegley,P. Bingham,Hieu Lam,Alexandra E Stupple,Aileen Kamal,A. Chueh,A. Cuzzupe,B. J. Morrow,B. Ren,Catalina Carrasco-Pozo,Chin Wee Godwin Tan,Dharmesh D. Bhuva,E. Allan,Elliot Surgenor,F. Vaillant,Havva Pehlivanoglu,Hendrik Falk,James R. Whittle,Janet Newman,Joseph Cursons,Judy P. Doherty,K. White,Laura MacPherson,Mark G. Devlin,M. Dennis,M. Hattarki,M. de Silva,M. Camerino,Miriam S. Butler,Olan Dolezal,P. Pilling,R. Foitzik,P. Stupple,H. Rachel Lagiakos,Scott E. Walker,Soroor Hediyeh-Zadeh,S. Nuttall,S. K. Spall,Susan A. Charman,T. Connor,Thomas S. Peat,Vicky M. Avery,Y. E. Bozikis,Yuqing Yang,Ming Zhang,Brendon J. Monahan,Anne K. Voss,Tim Thomas,I. Street,Sarah-Jane Dawson,Mark A. Dawson,Geoffrey J. Lindeman,Melissa J. Davis,Jane E. Visvader,Thomas A Paul +78 more
TL;DR: Researchers identified CTx-648, a potent and selective KAT6A/B inhibitor, which shows anti-tumor activity in ER+ breast cancer by inhibiting H3K23Ac and downregulating estrogen signaling, cell cycle, and stem cell pathways, offering a potential therapeutic strategy.
22
Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer.
Charlene Babra Waryah,Joseph Cursons,Momeneh Foroutan,Christian Pflueger,Edina C. Wang,Ramyar Molania,Anabel Sorolla,Christopher P Wallis,Colette Moses,Leandro Magalhães,Erik W. Thompson,Liam G. Fearnley,Christine L. Chaffer,Melissa J. Davis,Anthony T. Papenfuss,Andrew Redfern,Ryan Lister,Manel Esteller,Pilar Blancafort +18 more
TL;DR: In this paper , the authors used CRISPR/dCas9-mediated epigenetic editing to suppress the transcription factor ZEB1 in triple negative breast cancers (TNBCs).
11
Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma
Agustin Sgro,Joseph Cursons,Charlene Babra Waryah,Eleanor A. Woodward,Momeneh Foroutan,Ruqian Lyu,George C.T. Yeoh,Peter J. Leedman,Pilar Blancafort +8 more
TL;DR: In this paper , a toolbox of epigenetic effectors and gRNAs was used for patient-specific treatment of hepatocellular carcinoma (HCC) patients.
8
High temporal resolution RNA-seq time course data reveals widespread synchronous activation between mammalian lncRNAs and neighboring protein-coding genes
Walter Muskovic,Eve Slavich,Ben Maslen,Dominik C. Kaczorowski,Joseph Cursons,Edmund J. Crampin,Maria Kavallaris +6 more
TL;DR: The findings suggest broad-scale cis-regulatory roles for lncRNAs are not common and may instead indicate an origin as transcriptional by-products from active protein-coding gene promoters and enhancers.
Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin
Jean Berthelet,Momeneh Foroutan,Dharmesh D. Bhuva,Holly J. Whitfield,Farrah El-Saafin,Joseph Cursons,Antonin Serrano,Michal Merdas,Elgene Lim,Emmanuelle Charafe-Jauffret,Christophe Ginestier,Matthias Ernst,Frédéric Hollande,Rob Anderson,Bhupinder Pal,Belinda Yeo,Melissa J. Davis,Delphine Merino +17 more
TL;DR: A new gene signature is discovered to identify breast cancer tumors that are likely to respond to cisplatin in the absence of BRCA1 mutations, an important advance to accelerate the application of platinum-based therapies in patient groups that are not routinely treated with these drugs.